Syntocinon® & Syntometrine®: Rephrasing terminology to avoid errors

Oxytocin (Syntocinon®) and ergometrine with oxytocin (Syntometrine®) are two well-known brands of oxytocics in current use in maternity centres within the UK. It is common practice to refer to these drugs by their brand names. A subsequent shortening of Syntocinon® to ‘Synto’ in verbal communication has led to inadvertent administration of the wrong product. As a generic brand of oxytocin is now also readily available, it is quite possible for staff to select Syntometrine from the fridge when ‘Synto’ is requested as this is the only product that resembles this name. This risk is likely to further increase as new members of staff, unfamiliar with the Syntocinon® brand of oxytocin, commence practice.

Likewise, referring to the combination product by its generic name (ergometrine and oxytocin), or vice versa runs the risk of it being mistaken as just one or other of the ingredients rather than the combination product.

The National Reporting and Learning System (NRLS) reported 1157 patient safety incidences over a five year period (2013-2018) involving Syntocinon® or Syntometrine®. Of these, 39 incidences resulted in the incorrect drug being given. Discussion with colleagues working within maternity centres has identified near misses and actual errors possibly resulting from the terminology being used. Staff working under pressure may inadvertently confuse the two products or misread the drug name due to the historical practice of using the prefix ‘Synto’ for both products.

Recommendations

The UKCPA Womens Health Group would like to propose the following:

- All centres to stop using the terms ‘Synto’ and ‘Syntocinon®’. Oxytocin must be referred to only by its generic name.
- All centres to refer to the combination product as ‘Syntometrine®’.
- All health professionals referring to these drugs as ‘Synto’ be challenged by colleagues and clarification sought regarding which drug is intended before administration.
- All education facilities going forward refrain from using terminology other than that proposed in this paper.

In time, we hope that with our concerted efforts, the term ‘Synto’ will no longer be used and that this will result in the reduction of medication errors.
Syntocinon & Syntometrine: Rephrasing terminology to avoid errors
UKCPA Women’s Health Group Advisory Paper

Authors:

- **Christina Nurmahi**, Lead Pharmacist for Women and Newborn, University Hospital Southampton NHS Foundation Trust
- **Elaine Smith**, Lead Pharmacist for Women and Children, Chelsea and Westminster Hospital NHS Trust
- **Dr Nuttan Tanna**, Pharmacist Consultant, Women’s Health & Osteoporosis / Bone Health, London North West University Healthcare NHS Trust

Disclaimers & declarations of interest: None

Enquiries should be made to: Christina Nurmahi, Chair of UKCPA Women’s Health Group: christina.nurmahi@uhs.nhs.uk

Review date: February 2026

About UKCPA:
The UK Clinical Pharmacy Association (UKCPA) is a not-for-profit membership association which supports the pharmacy workforce to share best practice, network, collaborate, innovate and flourish. Our goal is to foster and support excellence in clinical pharmacy practice so that practitioners can provide outstanding patient care.

For more information: [www.ukclinicalpharmacy.org](http://www.ukclinicalpharmacy.org)

About the UKCPA Women’s Health Committee
The UKCPA Women’s Health Committee are dedicated clinical pharmacists working in the area of women’s health. They are committed to sharing best practice through education and development activities, developing professional curricula, and contributing their medicines expertise to national consultations and initiatives.

For more information: [www.ukclinicalpharmacy.org/groups/womens-health/](http://www.ukclinicalpharmacy.org/groups/womens-health/)